Ovarian Cancer GOG 1861

March 13, 2013

Location: The Hospital of Central Connecticut

A Randomized Phase II Evaluation of Single-Agent Bevacizumab and Combination Bevacizumab with Fosbretabulin Thromethamine in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma (Platinum Sensitive and Platinum Resistant are eligible-NO Refractory patients).